NEW YORK (
CHANGE IN RATINGS
upgraded at Argus from Hold to Buy, Argus Research said. Valuation call, based on a $10 price target. Natural gas now also appears less attractive, relative to coal.
rated new Neutral at Lazard. Stock is already pricing in solid growth for Soliris.
(AMGN - Get Report)
upgraded at Lazard from Sell to Buy, Lazard said. New analyst has a $101 price target. Company has strong growth prospects and an attractive pipeline.
downgraded at Credit Suisse from Outperform to Neutral, Credit Suisse said. Valuation call, based on a $75 price target.
downgraded to hold at TheStreet Ratings.
Alliance One International
downgraded to sell at TheStreet Ratings.
downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Company lacks near-term visibility. $6.50 price target.
upgraded at Canaccord from Hold to Buy, Canaccord Genuity said. $71 price target. Investors have overreacted and China can drive growth in the coming years.
rated new Neutral at UBS. $12.50 price target. Troubling near term, but more positive long term.
(GILD - Get Report)
downgraded at Lazard to Neutral, Lazard said. New analyst sees increased competition for the company's HCV franchise.
downgraded at BMO to Underperform, BMO Capital said. $14 price target. Company will likely continue to struggle for several quarters.
(HPQ - Get Report)
rated new Sell at UBS. $16 price target. CEO turnover, lack of focus, and poor financial results.
upgraded at Goldman from Neutral to Buy, Goldman Sachs said. $9 price target. Solid-state and networking businesses should drive margin expansion.
(NTAP - Get Report)
rated new Buy at UBS. $45 price target. Forecast above consensus growth and attractive valuation.
rated new Buy at Dahlman. $99 price target. Accommodations and Offshore segments should drive growth.
downgraded at BMO from Outperform to Market Perform, BMO Capital said. $55 price target. Company lacks near-term catalysts. Market Perform rating.
rated new Neutral at Lazard. Company lacks near-term visibility.
downgraded at DA Davidson from Buy to Neutral, Goldman Sachs said. $15 price target. Estimates also cut, given lower expected production rates.
upgraded at Credit Suisse from Neutral to Outperform, Credit Suisse said. $25 price target. Company is gaining market share.
rated new Buy at Lazard. $57 price target. ALS-2200 will likely be the company's main growth driver.
upgraded at Lazard to Buy, Lazard said. New analyst has a $36 price target. Obesity drug should drive growth over the next several quarters.
downgraded at JP Morgan from Neutral to Underweight, JP Morgan said. $14 price target. Company is seeing slower earnings growth.
WMS Industries downgraded at BofA/Merrill to Underperform, Bank of America/Merrill Lynch. $14 price target. Company is investing more into its interactive business.
WMS Industries downgraded at Nomura from Neutral to Reduce, Nomura said. $13 price target. Company is facing increased competition.
STOCK COMMENTS / EPS CHANGES
numbers lowered at Oppenheimer. Shares of APC now seen reaching $90, Oppenheimer said. Estimates also lowered on settlement. Outperform rating.
target raised at Jefferies to $95, Jefferies said. Underlying momentum. Buy rating.
numbers lowered at Jefferies. Shares of CBOU now seen reaching $16, Jefferies said. Estimates also lowered on K-Cup pains. Buy rating.
estimates, target boosted at BMO. Shares of CTSH now seen reaching $70, according to BMO Capital. Estimates also upped, given better pricing and more orders from top customers. Outperform rating.
estimates, target reduced at Keybanc. ESL estimates were cut through 2013, Keybanc said. Company lowered its guidance. Buy rating and new $66 price target.
estimates, target increased at Cantor. HCA estimates were raised through 2013, Cantor Fitzgerald said. Company is seeing better utilization trends. Buy rating and new $33 price target.
numbers lowered at Morgan Stanley. Shares of JCP now seen reaching $20, according to Morgan Stanley. Estimates also cut, as sales trends suggest reduced demand. Underweight rating.
added to US 1 List at BofA/Merrill. Fund performance and net inflows have been strong. $17 price target.
numbers cut at BofA/Merrill. TSN estimates were reduced through 2013, Bank of America/Merrill Lynch said. Company is facing higher grain costs and seeing lower consumer demand. Underperform rating and new $13 price target.
estimates lowered at Citigroup through 2013. Solid 2Q revenue growth, although light of forecast. $30 price target and Buy rating.
estimates, target raised at Credit Suisse. Shares of WRC now seen reaching $48, according to Credit Suisse. Estimates also increased, as the company is keeping costs and inventory down. Neutral rating.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on